PharmGen Science Discloses Governance Report: 80% Non-compliance of Key Indicators, Massive Net Loss Raises Shareholder Concerns
Only 3 out of 15 key governance indicators are met (electronic voting, avoiding peak shareholder meeting dates, board gender diversity), resulting in a 20% compliance rate, revealing weak shareholder protection and transparency
Recorded a net loss of 116.6 billion KRW in 2025, a sharp reversal from profit in the prior year; revenue slightly increased to 173.0 billion KRW but operating profit fell to 5.99 billion KRW
No dividends paid for the past three consecutive years; no dividend policy or predictability provided, inadequately protecting minority shareholder rights
Critical governance structures missing: CEO succession policy, enterprise risk management, dedicated internal audit department, outside director evaluation system, and audit committee
Largest shareholder holds only 19.87% while minority shareholders hold 70.23%, yet shareholder proposal procedures and minority protection policies are not established
[AI Summary]PharmGen Science's corporate governance report indicates high risk of shareholder value impairment due to low governance compliance, massive net loss, and absence of dividends; limited investment appeal unless concrete improvement plans are implemented